SCHEMBL2980047

SCHEMBL2980047

O=c1[nH]c(=O)n(COCc2ccccc2)c2sccc12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.54
TNKS2 Q9H2K2 2/20 0.44
PARP2 Q9UGN5 1/20 0.44
ERCC1 P07992 1/20 0.43
ERCC5 P28715 1/20 0.43
FEN1 P39748 1/20 0.43
ERCC4 Q92889 1/20 0.43
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
ADORA2B P29275 1/20 0.40
PDE1B Q01064 1/20 0.40
TK1 P04183 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.37
TNKS O95271 1/20 0.37
PARP1 P09874 1/20 0.37
PARP15 Q460N3 1/20 0.37
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
UPP1 Q16831 1/20 0.36
DAO P14920 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31257840 0.80 TNKS2 (0.45) ALDH1A1TNKS2PARP2ERCC1ERCC5
SCHEMBL6723373 0.78 ALDH1A1 (0.59) ALDH1A1CYP2C9CYP2C19TK1SMN1; SMN2
SCHEMBL6719602 0.72 ALDH1A1 (0.75) ALDH1A1CYP2C9CYP2C19TK1SMN1; SMN2
SCHEMBL6670689 0.71 ALDH1A1 (0.40) ALDH1A1TNKS2PARP2ERCC1ERCC5
SCHEMBL19994153 0.71 ERCC1 (0.36) ALDH1A1TNKS2PARP2ERCC1ERCC5
SCHEMBL7507593 0.70 DAO (0.53) ALDH1A1TNKS2ERCC1ERCC5FEN1
SCHEMBL27691590 0.69 ALDH1A1 (0.70) ALDH1A1CYP2C9CYP2C19TK1SMN1; SMN2
SCHEMBL27691593 0.69 ALDH1A1 (0.55) ALDH1A1CYP2C9CYP2C19TK1SMN1; SMN2
SCHEMBL9597854 0.68 ALDH1A1 (0.53) ALDH1A1CYP2C9CYP2C19TK1SMN1; SMN2
SCHEMBL27691591 0.68 ALDH1A1 (0.56) ALDH1A1CYP2C9CYP2C19TK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776868-B2 Substituted bicyclic and tricyclic thieno[2,3-d]pyrimidines as A2A adenosine receptor antagonists GILEAD PALO ALTO, INC. (US) 2010-08-17 US disclosed
US-20080188495-A1 A2A ADENOSINE RECEPTOR ANTAGONISTS CV THERAPEUTICS, INC. 2008-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188495-A1 A2A ADENOSINE RECEPTOR ANTAGONISTS ADORA2A, ADORA3, ADORA1 ALDH1A1 925/4885TNKS2 1554/4885PARP2 1800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.